Outset Medical (OM) to Release Earnings on Wednesday

Outset Medical (NASDAQ:OM) is anticipated to release its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect Outset Medical to post earnings of ($0.45) per share and revenue of $28.90 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Outset Medical Stock Up 2.5%

OM stock opened at $4.50 on Monday. The stock has a market capitalization of $81.69 million, a P/E ratio of -0.34 and a beta of 2.08. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. Outset Medical has a 1-year low of $3.10 and a 1-year high of $21.98. The business has a fifty day moving average price of $4.43 and a 200-day moving average price of $9.79.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OM. Stifel Nicolaus lowered their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday. BTIG Research restated a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a report on Tuesday, December 16th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Outset Medical has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Insider Buying and Selling

In other Outset Medical news, EVP Marc Nash sold 5,375 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president owned 42,785 shares in the company, valued at approximately $219,059.20. This represents a 11.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the sale, the chief executive officer directly owned 107,823 shares in the company, valued at $552,053.76. The trade was a 9.86% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 35,989 shares of company stock worth $180,073. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OM. Legal & General Group Plc purchased a new position in shares of Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its holdings in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in Outset Medical during the 2nd quarter worth $108,000. Quantbot Technologies LP purchased a new stake in shares of Outset Medical during the second quarter worth $152,000. Finally, JPMorgan Chase & Co. raised its position in shares of Outset Medical by 662.8% in the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock valued at $162,000 after buying an additional 7,344 shares during the last quarter.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.